SPF45/RBM17-dependent Splicing and Multidrug Resistance to Cancer Chemotherapy

Overview

Journal Mol Cell Oncol

Specialty Oncology

Date 2022 Apr 14

PMID 35419480

Authors

Kazuhiro Fukumura

Julian P Venables

Akila Mayeda

Affiliations

Soon will be listed here.

Abstract

The early splicing complex A occupies at least eighty nucleotides of intron, in which U2AF covers the polypyrimidine tract. SPF45 (RBM17) functionally substitutes for U2AF on a subset of short introns. Since SPF45 expression confers resistance to various anticancer drugs, SPF45-dependent splicing may play a critical role in multidrug resistance.

References

Niimi S, Nakagawa K, Yokota J, Tsunokawa Y, Nishio K, Terashima Y . Resistance to anticancer drugs in NIH3T3 cells transfected with c-myc and/or c-H-ras genes. Br J Cancer. 1991; 63(2):237-41. PMC: 1971793. DOI: 10.1038/bjc.1991.56. View

Liu Y, Conaway L, Rutherford Bethard J, Al-Ayoubi A, Thompson Bradley A, Zheng H . Phosphorylation of the alternative mRNA splicing factor 45 (SPF45) by Clk1 regulates its splice site utilization, cell migration and invasion. Nucleic Acids Res. 2013; 41(9):4949-62. PMC: 3643583. DOI: 10.1093/nar/gkt170. View

Lee K, Giltnane J, Balko J, Schwarz L, Guerrero-Zotano A, Hutchinson K . MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation. Cell Metab. 2017; 26(4):633-647.e7. PMC: 5650077. DOI: 10.1016/j.cmet.2017.09.009. View

Shimada M, Sasaki-Haraguchi N, Mayeda A . Identification and Validation of Evolutionarily Conserved Unusually Short Pre-mRNA Introns in the Human Genome. Int J Mol Sci. 2015; 16(5):10376-88. PMC: 4463651. DOI: 10.3390/ijms160510376. View

Wahl M, Will C, Luhrmann R . The spliceosome: design principles of a dynamic RNP machine. Cell. 2009; 136(4):701-18. DOI: 10.1016/j.cell.2009.02.009. View

Tan Q, Yalamanchili H, Park J, de Maio A, Lu H, Wan Y . Extensive cryptic splicing upon loss of RBM17 and TDP43 in neurodegeneration models. Hum Mol Genet. 2016; 25(23):5083-5093. PMC: 5968355. DOI: 10.1093/hmg/ddw337. View

Lu J, Li Q, Cai L, Zhu Z, Guan J, Wang C . RBM17 controls apoptosis and proliferation to promote Glioma progression. Biochem Biophys Res Commun. 2018; 505(1):20-28. DOI: 10.1016/j.bbrc.2018.09.056. View

Lallena M, Chalmers K, Llamazares S, Lamond A, Valcarcel J . Splicing regulation at the second catalytic step by Sex-lethal involves 3' splice site recognition by SPF45. Cell. 2002; 109(3):285-96. DOI: 10.1016/s0092-8674(02)00730-4. View

Fukumura K, Yoshimoto R, Sperotto L, Kang H, Hirose T, Inoue K . SPF45/RBM17-dependent, but not U2AF-dependent, splicing in a distinct subset of human short introns. Nat Commun. 2021; 12(1):4910. PMC: 8363638. DOI: 10.1038/s41467-021-24879-y. View

10.

Corsini L, Bonnal S, Bonna S, Basquin J, Hothorn M, Scheffzek K . U2AF-homology motif interactions are required for alternative splicing regulation by SPF45. Nat Struct Mol Biol. 2007; 14(7):620-9. DOI: 10.1038/nsmb1260. View

11.

Sasaki-Haraguchi N, Shimada M, Taniguchi I, Ohno M, Mayeda A . Mechanistic insights into human pre-mRNA splicing of human ultra-short introns: potential unusual mechanism identifies G-rich introns. Biochem Biophys Res Commun. 2012; 423(2):289-94. DOI: 10.1016/j.bbrc.2012.05.112. View

12.

Li C, Ge S, Zhou J, Peng J, Chen J, Dong S . Exploration of the effects of the CYCLOPS gene RBM17 in hepatocellular carcinoma. PLoS One. 2020; 15(6):e0234062. PMC: 7272028. DOI: 10.1371/journal.pone.0234062. View

13.

Sampath J, Long P, Shepard R, Xia X, Devanarayan V, Sandusky G . Human SPF45, a splicing factor, has limited expression in normal tissues, is overexpressed in many tumors, and can confer a multidrug-resistant phenotype to cells. Am J Pathol. 2003; 163(5):1781-90. PMC: 1892446. DOI: 10.1016/S0002-9440(10)63538-9. View

14.

Perry 3rd W, Shepard R, Sampath J, Yaden B, Chin W, Iversen P . Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed--a phenotype partially reversed by selective estrogen receptor modulators. Cancer Res. 2005; 65(15):6593-600. DOI: 10.1158/0008-5472.CAN-03-3675. View